Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Vaxil Bio Ltd

Healthcare CA VXL

0.18CAD
0.00(0%)

Last update at 2026-06-19T13:30:00Z

Day Range

0.180.18
LowHigh

52 Week Range

0.010.50
LowHigh

Fundamentals

  • Previous Close 0.18
  • Market Cap0.56M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.25200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -0.17800M -0.00025M -0.58400M -0.98600M -1.35800M
Minority interest - - - - -
Net income -0.17800M -0.00025M -0.58400M -0.98600M -1.36900M
Selling general administrative 0.18M 0.00012M 0.24M 0.43M 0.72M
Selling and marketing expenses - 0.00002M - - -
Gross profit - - -0.00200M -0.02500M -0.05700M
Reconciled depreciation - 0.00000M 0.00200M 0.03M 0.06M
Ebit - -0.16815M -0.58400M -0.98600M -1.34700M
Ebitda - -0.00025M -0.58200M -0.96100M -1.29000M
Depreciation and amortization - 0.17M 0.00200M 0.03M 0.06M
Non operating income net other - - - - -
Operating income -0.19600M -0.00025M -0.58400M -0.98600M -1.34700M
Other operating expenses - 0.00025M 0.58M 0.99M 1.35M
Interest expense - - - 0.00400M 0.01M
Tax provision - - - - -
Interest income 0.02M - - - -
Net interest income 0.02M - - 0.00400M -0.01100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.01M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.20M 0.00025M 0.58M 0.99M 1.35M
Cost of revenue - - 0.00200M 0.03M 0.06M
Total other income expense net - 0.00500M - - -0.01100M
Discontinued operations - - - - -
Net income from continuing ops -0.17800M -0.25400M -0.58400M -0.98600M -1.35800M
Net income applicable to common shares - - - -0.98600M -1.35800M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.73M 0.98M 1.54M 2.29M 1.66M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.00004M - - -
Total liab 0.02M 0.09M 0.41M 0.58M 0.86M
Total stockholder equity 0.72M 0.89M 1.14M 1.70M 0.80M
Deferred long term liab - - - - -
Other current liab - 0.08M - - 0.26M
Common stock - 16.07M 16.07M 16.07M 13.86M
Capital stock 16.07M 16.07M 16.07M 16.07M 13.86M
Retained earnings -19.53500M -19.35700M -19.10300M -18.51900M -17.53300M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.45M 0.94M 1.51M 2.24M 1.51M
Cash and equivalents - - - - -
Total current liabilities 0.02M 0.09M 0.41M 0.58M 0.86M
Current deferred revenue - - - - -
Net debt - -0.93800M - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 0.00000M - 0.28M 0.69M
Property plant equipment - - - 0.00200M 0.03M
Total current assets 0.73M 0.98M 1.54M 2.28M 1.63M
Long term investments - - - - -
Net tangible assets - - - 1.70M 0.80M
Short term investments - - - - -
Net receivables - 0.02M - 0.04M 0.03M
Long term debt - - - - -
Inventory - 0.02M - - -
Accounts payable - 0.00009M - 0.58M 0.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 4.17M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00200M 0.03M
Capital lease obligations - - - 0.00000M 0.00900M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.25000M - - - -
Change to liabilities - - 0.00000M -0.27500M -0.03000M
Total cashflows from investing activities - - - - -
Net borrowings - - - -0.00900M -0.02100M
Total cash from financing activities - - 0.04M 1.81M 2.56M
Change to operating activities - - - - 0.16M
Net income -0.17800M -0.25400M -0.58400M -0.98600M -1.35800M
Change in cash -0.49000M -0.57200M -0.73100M 0.73M 1.43M
Begin period cash flow 0.94M 1.51M 2.24M 1.51M 0.08M
End period cash flow 0.45M 0.94M 1.51M 2.24M 1.51M
Total cash from operating activities -0.24000M -0.56100M -0.73400M -1.08400M -1.10300M
Issuance of capital stock - - - 0.00000M 0.76M
Depreciation - 0.00000M 0.00200M 0.03M 0.06M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - 0.28M -
Change to account receivables 0.02M -0.00700M 0.01M 0.08M -0.09700M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - 0.00181M 1.86M
Change to netincome - - - 0.07M 0.16M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04900M -0.32700M -0.16900M -0.19300M 0.04M
Stock based compensation 0.00500M 0.02M 0.02M 0.07M 0.15M
Other non cash items -0.01800M -0.00032M 0.01000M 0.04M 0.01M
Free cash flow -0.24000M -0.56100M -0.73400M -1.08400M -1.10300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
VXL
Vaxil Bio Ltd		 - -% 0.18 - - - 0.57 -1.8431
SHRX
Sharp Therapeutics Corp.		 - -% 1.00 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.79% 0.55 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.07 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.56 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.

Vaxil Bio Ltd

559 Briar Hill Avenue, Toronto, ON, Canada, M5N 1N1

Key Executives

Name Title Year Born
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA Chairman & CFO 1973
Dr. Yuval Avnir Ph.D. Head of R&D & CEO NA
Dr. Riva Kovjazin M.D. Sr. Scientist & Member of Scientific Advisory Board NA
Mr. David Goren CEO & Chairman NA
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CFO & Director 1973
Dr. Riva Kovjazin M.D. Senior Scientist & Member of Scientific Advisory Board NA
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CEO & Chairman 1973
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA Chief Financial Officer 1952

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions